Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IGF-I is an important growth factor for the mammary gland. We evaluated the relationship of the IGF-I CA(n) polymorphism with breast cancer risk in Caucasian postmenopausal women and performed a meta-analysis of published data. The IGF-I CA(n) polymorphism was genotyped in 4091 from the Rotterdam Study. A disease-free survival analysis was performed along with a meta-analysis of all available data on IGF-I CA(n) polymorphism and breast cancer risk. During follow-up 159 women were diagnosed with breast cancer. The disease-free survival analysis adjusted for age at entry, age at menopause, body mass index and waist hip ratio yielded a HR=0.97 (95% CI=0.59-1.58) for CA(19) non-carriers against carriers. The meta-analysis using the random-effects model gave a pooled OR of 1.26 (95% CI=0.95-1.82) for IGF-I CA(19) non-carriers versus CA(19) homozygous carriers. According to these results, the IGF-I CA(19) promoter polymorphism is not likely to predict the risk of breast cancer.

Original publication

DOI

10.1016/j.ejca.2007.04.026

Type

Journal article

Journal

European journal of cancer (Oxford, England : 1990)

Publication Date

07/2007

Volume

43

Pages

1718 - 1722

Addresses

Epidemiology & Biostatistics Department, Erasmus MC, Rotterdam, The Netherlands.

Keywords

Humans, Breast Neoplasms, Insulin-Like Growth Factor I, Risk Factors, Postmenopause, Genotype, Heterozygote, Homozygote, Polymorphism, Genetic, Aged, Middle Aged, Female